RxDoctor Payments Data

Jennifer Reams, DO

Rheumatology · Bridgeport, WVNPI 1780002204

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 41.5% of the total. Reporting peaked in 2019 at $763 and has fallen 84.0% since, to $122 in 2025. That places this record below the midpoint for rheumatology clinicians in WV, where the typical reported total is $1,762.

$1,762in general payments, 2019–2025

Across 44 payments — averaging $40.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$731
  • AbbVie$335
  • Novartis$181
  • Johnson & Johnson$179
  • Regeneron Healthcare Solutions, Inc.$125
  • AstraZeneca$108
  • plus $102 from 3 others

What the payments were for

  • Food & beverage$1,762100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,762 in reported general payments places this provider in the 50th percentile of 26 rheumatology providers in West Virginia.

See all rheumatology providers in West Virginia

Medicare billing

Part B allowed, 2024
$46,424
Medicare patients
197
Services billed
634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab148$1,118,347
Enbrel SureclickEtanercept94$701,848
TremfyaGuselkumab18$235,330
RinvoqUpadacitinib30$190,170
KevzaraSarilumab22$93,917
Orencia ClickjectAbatacept12$68,694
Actemra ActpenTocilizumab15$43,224
Mycophenolate Mofetil85$14,172
Hydroxychloroquine Sulfate296$8,580
MethotrexateMethotrexate Sodium341$6,650
Leflunomide88$2,453
Azathioprine68$2,182
Prednisone326$1,949
Sulfasalazine55$1,690
Tramadol Hcl135$1,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$179$235,33018 claims
AbbVieRinvoq$335$190,17030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 26 rheumatology providers in West Virginia.

Other rheumatology in Bridgeport

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →